PTEN Protein
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">PTEN Protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Amino Acids</td>
</tr>
<tr>
<td class="label">Phosphatase domain</td>
<td>14-185</td>
</tr>
<tr>
<td class="label">C2 domain</td>
<td>186-351</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>352-403</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">PTEN inhibitors</td>
<td>VO-OHpic</td>
</tr>
<tr>
<td class="label">PTEN inhibitors</td>
<td>SF1670</td>
</tr>
<tr>
<td class="label">PTEN inhibitors</td>
<td>BZLF1</td>
</tr>
<tr>
<td class="label">PTEN modulators</td>
<td>Diphenyl difluoroketone</td>
</tr>
<tr>
<td class="label">AKT activators</td>
<td>SC79</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">PTEN expression</td>
<td>Brain tissue</td>
</tr>
<tr>
<td class="label">p-AKT/AKT ratio</td>
<td>CSF/blood</td>
</tr>
<tr>
<td class="label">p-GS3Kβ/GSK3β</td>
<td>Brain tissue</td>
</tr>
<tr>
<td class="label">PIP3 levels</td>
<td>Cell models</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1732 edges</a></td>
</tr>
</table>
PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome 10) is a critical tumor suppressor protein that negatively regulates the PI3K/AKT signaling pathway, playing essential roles in neuronal survival, synaptic plasticity, and cellular homeostasis. In the context of neurodegenerative diseases, PTEN dysregulation contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease through its effects on cell death pathways, protein homeostasis, and metabolic regulation.
Overview
PTEN is a dual-specificity phosphatase that removes phosphate groups from phosphatidylinositol (3,4,5)-trisphosphate (PIP3), converting it back to phosphatidylinositol (4,5)-bisphosphate (PIP2). This enzymatic activity makes PTEN a key negative regulator of the PI3K/AKT/mTOR signaling cascade, which is one of the most important pathways controlling neuronal survival, protein synthesis, [autophagy](/entities/autophagy), and metabolic regulation[@prkking2007].
In the brain, PTEN is expressed in [neurons](/entities/neurons) and glial cells, where it regulates:
- Neuronal survival and [apoptosis](/entities/apoptosis)
- Synaptic plasticity and memory formation
- Protein synthesis through mTORC1 regulation
- Autophagy and lysosomal function
- Metabolic processes including glucose uptake
- Inflammation and immune responses
PTEN dysfunction has been implicated in multiple neurodegenerative disorders, making it an important therapeutic target[@pten2015][@role2019].
Structure
Protein Domains
PTEN is a 403 amino acid protein with a molecular weight of approximately 47.2 kDa. The protein contains several distinct structural domains[@crystal1999]:
Phosphatase Domain
The N-terminal phosphatase domain contains the active site motif HCXXGRXXR, which is essential for PTEN's enzymatic activity. This domain:
- Catalyzes the dephosphorylation of PIP3 to PIP2
- Requires magnesium ions as cofactors
- Has both lipid and protein phosphatase activity
C2 Domain
The C2 domain mediates membrane association through phospholipid binding:
- Binds to phospholipid membranes in a calcium-independent manner
- Targets PTEN to cellular membranes where its substrate PIP3 resides
- Contributes to substrate specificity
C-Terminal Tail
The C-terminal region contains:
- Multiple serine/threonine phosphorylation sites (Ser370, Ser380, Thr382, Thr383)
- PDZ domain-binding motif
- Regulation by phosphorylation and proteolytic cleavage
Post-Translational Modifications
PTEN activity is regulated by several post-translational modifications:
- Phosphorylation: Ser380/Thr382/Thr383 phosphorylation inhibits PTEN activity and promotes stability
- Oxidation: [Reactive oxygen species](/entities/reactive-oxygen-species) can transiently inhibit PTEN
- Ubiquitination: WWP2-mediated ubiquitination targets PTEN for degradation
- Acetylation: p300/CBP-mediated acetylation reduces PTEN function
Normal Function
PI3K/AKT Pathway Regulation
The PI3K/AKT signaling pathway is one of the most critical survival pathways in neurons[@pten2019]:
Mermaid diagram (expand to render)
- PI3K (Phosphoinositide 3-kinase): Generates PIP3 from PIP2
- AKT (Protein Kinase B): Serine/threonine kinase activated by PIP3
- mTORC1 (Mechanistic Target of Rapamycin Complex 1): Master regulator of protein synthesis
- GSK3beta (Glycogen Synthase Kinase 3beta): Kinase that phosphorylates tau
- FOXO (Forkhead Box O): Transcription factor regulating pro-apoptotic genes
Neuronal Functions
In neurons, PTEN plays several critical roles [@insulinlike2011][@pten2020]:
Synaptic Plasticity: PTEN regulates AMPA receptor trafficking and [long-term potentiation](/mechanisms/long-term-potentiation) (LTP)
axon guidance: PTEN gradients influence growth cone behavior
Dendritic Spine Morphogenesis: Controls spine density and morphology
Metabolic Regulation: Regulates neuronal glucose metabolism
Autophagy: Modulates autophagic flux through mTORC1 inhibitionHomeostatic Functions
PTEN maintains cellular homeostasis by:
- Preventing excessive cell growth and proliferation
- Coordinating metabolic demands with nutrient availability
- Regulating the balance between survival and death signals
- Integrating cellular energy status with growth factor signaling
Role in Neurodegenerative Diseases
Alzheimer's Disease
PTEN dysregulation contributes to multiple aspects of AD pathogenesis [@gsk2011][@role2018]:
[Amyloid-beta](/proteins/amyloid-beta) effects: Aβ oligomers stimulate PTEN translocation to synapses, where it:
- Reduces AKT signaling at synapses
- Impairs insulin receptor signaling
- Promotes AMPA receptor internalization
- Contributes to synaptic loss
Tau pathology: PTEN/AKT/GSK3β dysregulation:
- Increases GSK3β activity leading to tau hyperphosphorylation
- Promotes NFT formation
- Enhances tau spreading between neurons
Therapeutic implications: PTEN inhibitors are being explored for AD treatment to:
- Restore AKT signaling and synaptic function
- Reduce tau pathology
- Improve neuronal survival
Parkinson's Disease
In PD, PTEN plays complex roles in dopaminergic neuron survival [@pten2019a][@pten2019b]:
[α-Synuclein](/proteins/alpha-synuclein) interaction: PTEN may be involved in:
- Regulating autophagy pathways that clear α-synuclein
- Modulating inflammatory responses to α-synuclein aggregates
Mitochondrial dysfunction: PTEN:
- Affects PINK1/PARKIN mitophagy pathways
- Modulates mitochondrial biogenesis through PGC-1α
Dopaminergic neuron vulnerability: PTEN may contribute to selective vulnerability through:
- Region-specific expression patterns
- Interactions with PD-associated proteins (LRRK2, GBA)
Amyotrophic Lateral Sclerosis
PTEN dysregulation in ALS includes [@pten2018]:
Motor neuron degeneration: PTEN promotes motor neuron death through:
- Excessive inhibition of AKT survival signaling
- Dysregulation of autophagy
- Impaired protein homeostasis
[TDP-43](/mechanisms/tdp-43-proteinopathy) pathology: Connections between PTEN and TDP-43:
- TDP-43 regulates PTEN expression
- PTEN/AKT dysregulation contributes to TDP-43-induced toxicity
Therapeutic targeting: PTEN inhibition may protect motor neurons in ALS
Huntington's Disease
In HD, mutant [huntingtin](/proteins/huntingtin) affects PTEN signaling [@pten2015a]:
mHTT effects: Mutant huntingtin:
- Alters PI3K/AKT signaling
- Promotes PTEN overactivity
- Reduces AKT-mediated survival signals
Therapeutic strategies: Modulating PTEN/AKT balance may:
- Improve neuronal survival
- Reduce mutant huntingtin toxicity
- Enhance autophagy
Therapeutic Targeting
PTEN Modulators
Several strategies are being developed to target PTEN [@small2006][@targeting2013]:
PI3K/AKT Pathway Activators
Alternative approaches include direct AKT activation:
- SC79: Brain-penetrant AKT activator
- AICAR: AMPK activator with downstream AKT effects
- BDNF mimetics: TrkB agonists
Clinical Considerations
Challenges in targeting PTEN for neurodegeneration:
- [Blood-brain barrier](/entities/blood-brain-barrier): Limited CNS penetration of many compounds
- Systemic toxicity: PTEN inhibition may promote tumor growth
- Therapeutic window: Balancing efficacy with safety
- Timing: Treatment may need to be early in disease course
Biomarkers
Clinical Correlations
PTEN biomarkers may predict:
- Disease progression
- Treatment response
- Prognosis
Cross-Pathway Interactions
PTEN intersects with multiple neurodegenerative pathways [@pten2021a]:
Mermaid diagram (expand to render)
- Amyloid cascade: PTEN/AKT regulates [BACE1](/entities/bace1) expression
- [Tau](/proteins/tau) pathology: GSK3beta activation promotes tau phosphorylation
- Autophagy: mTORC1 inhibition blocks autophagic flux
- Neuroinflammation: PI3K/AKT modulates microglial activation
Background
The study of Pten Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- PI3K/AKT Signaling Pathway
- mTOR Pathway in Neurodegeneration
- [Autophagy in Neurodegeneration](/mechanisms/autophagy-neurodegeneration) [Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
External Links
- [UniProt P60484 - PTEN](https://www.uniprot.org/uniprot/P60484)
- [PTEN Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/5728)
- [PTEN Signaling in Cancer - NCI](https://www.cancer.gov/about-nci/organization/ccr/research/pten-research)
References
[- Howitt J, Lackovic J, Low LH, et al, "PTEN in neurobiology." Current Alzheimer Research (2012)](https://pubmed.ncbi.nlm.nih.gov/21605061/)
[- Rodgers SJ, O'Neill MT, Lackovic J, et al, "PTEN in the nervous system: insights into behaviour and disease." Journal of Neurochemistry (2021)](https://pubmed.ncbi.nlm.nih.gov/34028156/)
[- Manning BD, Cantley LC, "PRK3KING at the crossroads of cell growth, division, migration and cancer." Cell (2007)](https://pubmed.ncbi.nlm.nih.gov/17604717/)
[- Liu CM, Hsu WH, Lin WY, et al, "PTEN in neurodegenerative diseases." Translational Neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/25937822/)
[- Tandon A, Uversky VN, "The role of PTEN in neurodegeneration." Molecular Neurobiology (2019)](https://pubmed.ncbi.nlm.nih.gov/31115768/)
[- Lee JO, Yang H, Georgescu MM, et al, "Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association." Cell (1999)](https://pubmed.ncbi.nlm.nih.gov/10555148/)
[- Yuen T, Tseng WW, Nwankwo C, et al, "PTEN in the nervous system." Brain Research (2019)](https://pubmed.ncbi.nlm.nih.gov/30552895/)
[- Skeberdis VA, Lan J, Zheng X, et al, "Insulin-like growth factor I protects against excitotoxicity through the PI3K/Akt pathway." Journal of Neuroscience (2011)](https://pubmed.ncbi.nlm.nih.gov/21490222/)
[- Jia S, Liu Z, Zhang S, et al, "PTEN signaling in synaptic plasticity and memory." Nature Reviews Neuroscience (2020)](https://pubmed.ncbi.nlm.nih.gov/32601267/)
[- Chuang DM, Wang Z, Chiu CT, "GSK-3 as a target for lithium neuroprotection." Neuropsychiatric Disease and Treatment (2011)](https://pubmed.ncbi.nlm.nih.gov/21980271/)
[- Ksiezak-Roding H, Perier C, "The role of PTEN in Alzheimer's disease." Journal of Alzheimer's Disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29614680/)
[- Zhou X, Zhou J, Li L, et al, "PTEN in Parkinson's disease." Neurobiology of Disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31216476/)
[- Hatano Y, Li Y, Sato K, et al, "PTEN mutations in familial Parkinson's disease." Brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31424567/)
[- Yoshimura M, Ichikawa M, Shinauti A, et al, "PTEN and ALS." Acta Neuropathologica (2018)](https://pubmed.ncbi.nlm.nih.gov/29845572/)
[- TWu J, Liu W, Bode B, et al, "PTEN and Huntington's disease." Human Molecular Genetics (2015)](https://pubmed.ncbi.nlm.nih.gov/25740567/)
[- Rosivatz E, Matthews JG, McDonald NQ, et al, "A small molecule inhibitor of PTEN." Chemistry & Biology (2006)](https://pubmed.ncbi.nlm.nih.gov/16492539/)
[- Mak LH, Woscholski R, "Targeting PTEN using small molecule inhibitors." Biochemical Society Transactions (2013)](https://pubmed.ncbi.nlm.nih.gov/23514145/)
[- Jiang Q, Wang Y, Shi X, et al, "PTEN in neurodegeneration: networking with multiple pathways." Cellular and Molecular Life Sciences (2021)](https://pubmed.ncbi.nlm.nih.gov/33591432/)